Klaassen T, Ho Pian K L, Westenberg H G, den Boer J A, van Praag H M
Department of Psychiatry and Neuropsychology, Maastricht University, The Netherlands.
Psychiatry Res. 1998 Jul 13;79(3):207-12. doi: 10.1016/s0165-1781(98)00044-4.
meta-Chlorophenylpiperazine (mCPP) is a non-selective 5-HT-receptor agonist/antagonist that is used extensively in psychiatry to assess central serotonergic function. We report on three patients who developed symptoms of the serotonin syndrome when they participated in an mCPP (0.5 mg/kg body weight p.o.) challenge test as part of a research protocol. They had relatively high plasma mCPP concentrations. The syndrome did not occur in normal volunteers who had comparable plasma concentrations of mCPP. Investigators should be aware of the possible occurrence of the serotonin syndrome after a single oral dose of mCPP.
间氯苯哌嗪（mCPP）是一种非选择性5-羟色胺受体激动剂/拮抗剂，在精神病学领域广泛用于评估中枢5-羟色胺能功能。我们报告了3例患者，他们在参与一项研究方案中的mCPP（口服0.5mg/kg体重）激发试验时出现了血清素综合征症状。他们的血浆mCPP浓度相对较高。在血浆mCPP浓度相当的正常志愿者中并未出现该综合征。研究人员应意识到单次口服mCPP后可能会发生血清素综合征。
